All HER receptors have prognostic impact on BC disease [21–23]; however, the extent to which HER1, HER3, and HER4 affect the sensitivity of ER-positive BC cancers to TAM treatment is hardly known. The gene discussed is ERBB4; the disease is breast cancer.